Recent advances in gout drugs
Authors:
- 29 October 2022
- journal article
- review article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 245 (Pt 1) , 114890
Abstract
No abstract availableKeywords
This publication has 124 references indexed in Scilit:
- Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensionsAnnals of the Rheumatic Diseases, 2012
- Uric acid as a danger signal in gout and its comorbiditiesNature Reviews Rheumatology, 2012
- Sensing and reacting to microbes through the inflammasomesNature Immunology, 2012
- URAT1 mutations cause renal hypouricemia type 1 in Iraqi JewsNephrology Dialysis Transplantation, 2010
- Crystal Structures of Urate Bound Form of Xanthine Oxidoreductase: Substrate Orientation and Structure of the Key Reaction IntermediateJournal of the American Chemical Society, 2010
- Glyburide inhibits the Cryopyrin/Nalp3 inflammasomeJournal of Cell Biology, 2009
- Randomized controlled trial design in rheumatoid arthritis: the past decadeArthritis Research & Therapy, 2009
- Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signalingProceedings of the National Academy of Sciences, 2007
- Cryopyrin activates the inflammasome in response to toxins and ATPNature, 2006
- Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan MetaboliteScience, 2005